Alzheimer's is quickly becoming an epidemic around the world.There are many reasons for this, including and aging population, the baby boomer demographic, and earlier disease diagnosis.
Wedge Therapeutics believes that the market is ready for a more widely accepted treatment option for many neurodegenerative patient populations. That's why it came up with the Sphenoid and Olfactory Nerve Stimulation™ (SONS™*) System. Now it's possible, for the first time, to induce Deep Brain Stimulation (DBS) from outside the brain while being simple to administer, with the least expenses, without surgery and with the least amount of complications.
Alzheimer's disease is a logical focus for neuronal network stimulation treatment because its proposed mechanism of action of stimulating neuronal network activity may relate to the underlying etiology of Alzheimer's disease. The pathological processes leading to Alzheimer's disease with memory loss, include the accumulation of beta amyloid protein, the deposition of amyloid plaque and the disruption of neural network activity, a loss of synaptic function, and eventual neuronal death.
SONS™ therapeutic stimulation strategy targets the major nerve centers located in the olfactory mucosa and the sphenoid sinus that are connected to the front and the base of the brain by millions of electrical fibers. These nerve centers are connected to memory centers which communicate with each other through the transmission of milliamps of electricity, which activates memory. It is envisioned that the SONS System™ will jump start these nerve centers and activate sleeping neurons to bring back memory and correct the lack of neurotransmitters in the brain.